Eye Meds Now

 Quick Ophthalmic Drug Search



223 items found
CROMOLYN (cromolyn sodium ophthalmic (4%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Mast Cell Stabilizers
Indications/Usage:

Indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis and vernal keratitis.


Typical Dosing:  

►Vernal keratoconjunctivitis, vernal conjunctivitis and vernal keratitis:

  • Instill 1 – 2 drop(s) in each eye 4 – 6 times daily at regular intervals.
  • Patients should be advised that the effect of therapy is dependent upon administration at regular intervals, as directed.
  • Symptomatic response to therapy (decreased itching, tearing, redness, and discharge) is usually evident within a few days, but longer treatment for up to 6 weeks is sometimes required. Once symptomatic improvement has been established, therapy should be continued for as long as needed to sustain improvement.
  • If required, corticosteroids may be used concomitantly with cromolyn sodium ophthalmic solution 4%.

How Supplied:  
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store between 59° – 77°F (15° – 25°C). 
  • Protect from light.
  • Store in original carton. 
  • Keep tightly closed. 
  • Replace cap immediately after use.


CYCLOGYL (cyclopentolate hydrochloride (0.5%; 1%; 2%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegics
Indications/Usage:

Used to produce mydriasis and cycloplegia.


Typical Dosing:  

►Mydriasis and cycloplegia:

  • Adults: 
    • Instill 1 – 2 drops of 0.5%, 1%, or 2% solution into the eye. May repeat in 5 – 10 minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days.
  • Children: 
    • Instill 1 – 2 drops of 0.5%, 1%, or 2% solution into the eye. May repeat in 5 – 10 minutes with a second application of 0.5% or 1% solution if necessary.
  • Small infants:
    • A single instillation of 1 drop of 0.5% solution into the eye. To minimize absorption, apply pressure over the nasolacrimal sac for 2 3 minutes.
    • Observe infant closely for 30 minutes following instillation.
  • Individuals with heavily pigmented irides may require higher strengths.
  • Additional information for pediatric use is in Notes below: 

How Supplied:  
  • 0.5% ophthalmic solution:
    • 15 mL bottles
  • 1% ophthalmic solution:
    • 2 mL bottles
    • 5 mL bottles
    • 15 mL bottles
  • 2% ophthalmic solution:
    • 2 mL bottles
    • 5 mL bottles
    • 15 mL bottles

Preservatives:  

benzalkonium chloride, disodium edetate


Storage:  
  • Store at 46° – 77°F (8° – 25°C).


CYCLOMYDRIL (cyclopentolate hydrochloride (0.2%) – phenylephrine hydrochloride (1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegic and Mydriatic Combinations
Indications/Usage:

Indicated for the production of mydriasis.


Typical Dosing:  

►Mydriasis: 

  • Instill 1 drop into each eye every 5 – 10 minutes.
  • To minimize systemic absorption, apply pressure over the nasolacrimal sac for 2 – 3 minutes following instillation.
  • Observe infants closely for at least 30 minutes.
  • Additional information for pediatric use is in Notes below: 

How Supplied:  
  • 2 mL bottles
  • 5 mL bottles

Preservatives:  

benzalkonium chloride, disodium edetate


Storage:  
  • Store at 46° – 77°F (8° – 25°C).


CYCLOPENTOLATE (cyclopentolate hydrochloride (0.5%; 1%; 2%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Cycloplegics
Indications/Usage:

Used to produce mydriasis and cycloplegia.


Typical Dosing:  

►Mydriasis and cycloplegia:

  • Adults:
    • Instill 1 – 2 drops of 0.5%, 1%, or 2% solution into the eye. May repeat in 5 – 10 minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days.
  • Children:
    • Instill 1 – 2 drops of 0.5%, 1%, or 2% solution into the eye. May repeat in 5 – 10 minutes with a second application of 0.5% or 1% solution if necessary.
  • Small infants:
    • Single instillation of 1 drop of 0.5% solution into the eye. To minimize absorption, apply pressure over the nasolacrimal sac for 2 – 3 minutes.
    • Observe infant closely for at least 30 minutes following instillation. 
  • Individuals with heavily pigmented irides may require higher strengths.
  • Additional information for pediatric use is in Notes below: 

How Supplied:  
  • 0.5% ophthalmic solution:
    • 15 mL bottles
  • 1% ophthalmic solution:
    • 2 mL bottles
    • 5 mL bottles
    • 15 mL bottles
  • 2% ophthalmic solution:
    • 2 mL bottles
    • 5 mL bottles
    • 15 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).
  • Keep tightly closed.
  • KEEP OUT OF THE REACH OF CHILDREN.


CYSTARAN (cysteamine hydrochloride (0.44%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Other Medications
Indications/Usage:

Indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.


Typical Dosing:  

►Corneal cystine crystal accumulation in patients with cystinosis: 

  • Instill 1 drop into each eye, every waking hour. 
  • Do not touch dropper tip to any surface, as this may contaminate the solution.
  • Discard after 1 week of use.

How Supplied:  
  • 15 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store in freezer at –13° to 5°F (–25° to –15°C).
  • Thaw for approximately 24 hours before use.
  • Store thawed bottle at 36° – 77°F (2° – 25°C) for up to 1 week.
  • Do not refreeze.
  • Discard after 1 week of use.


Assistance: Payment Assistance

DESLORATADINE (desloratadine (5 mg) tablets, film coated; (2.5 mg; 5 mg) tablets, orally disintegrating; (0.5 mg/mL) oral solution)
Prescription
Oral
Oral Disintegrating Tablets
Oral Solution
Tablets
Antihistamines
Indications/Usage:

Indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older and for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older.


Typical Dosing:  

Nasal and non-nasal symptoms of seasonal or perennial allergic rhinitis:

  • Tablets or oral disintegrating tablets:
    • Adults and adolescents 12 years of age, recommended:
      • One 5 mg tablet once daily.
    • Adults with hepatic or renal impairment:
      • A starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data.
    • Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [See Clinical Pharmacology (12.3) in package insert].
  • Oral solution:
    • Adults and adolescents 12 years of age, recommended:
      • 10 mL (5 mg) once daily.
    • Children 6 – 11 years of age, recommended:
      • 5 mL (2.5 mg) once daily.
    • Children 12 months – 5 years of age, recommended:
      • 2.5 mL (1.25 mg) once daily.
    • Children 6 – 11 months of age, recommended:
      • 2 mL (1 mg) once daily.

How Supplied:  
  • Tablets:
    • 5 mg tablets
  • Tablets, orally disintegrating:
    • 2.5 mg tablets
    • 5 mg tablets
  • Oral solution:
    • 0.5 mg/mL solution

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Tablets:
    • Store at 77°F (25°C); excursions permitted to 59° – 86°F (15° – 30°C).
    • Heat sensitive; avoid exposure at or above 86°F (30°C).
  • Oral solution:
    • Store at 77°F (25°C); excursions permitted to 59° – 86°F (15° – 30°C).
    • Protect from light.


DEXAMETHASONE SODIUM PHOSPHATE (dexamethasone sodium phosphate (0.1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Allergy Corticosteroids, Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies.

This medication has a broad FDA approval for "corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and corneal injury from chemical, radiation, or thermal burns or penetration of foreign bodies:

  • Instill 1 – 2 drops into the conjunctival sac every hour during the day and every 2 hours during the night as initial therapy.
  • When a favorable response is observed, reduce dosage to 1 drop every 4 hours. Later, further reduction in dosage to 1 drop 3 – 4 times daily may suffice to control symptoms.

How Supplied:  
  • 5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store between 59° – 77°F (15° – 25°C).


DICLOFENAC (diclofenac sodium (0.1%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
NSAIDS
Indications/Usage:

Indicated for the treatment of post-operative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery.


Typical Dosing:  

►Post-operative inflammation in patients who have undergone cataract extraction and pain and photophobia in patients undergoing corneal refractive surgery:

►Cataract surgery:

  • Instill 1 drop into the affected eye(s) 4 times daily, beginning 24 hours after cataract surgery and continuing throughout the first 2 weeks of the post-operative period. 

►Corneal refractive surgery:

  • Instill 1 – 2 drops into the operative eye within the hour prior to corneal refractive surgery. Within 15 minutes after surgery, 1 – 2 drops should be applied to the operative eye and continued 4 times daily, for up to 3 days.

How Supplied:  
  • 2.5 mL bottles
  • 5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


DICLOXACILLIN (dicloxacillin sodium (250 mg; 500 mg) capsules)
Prescription
Oral
Capsules
Antibiotics
Indications/Usage:

Indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug.

Consult package insert for additional information.

This medication has a broad FDA approval for "infections caused by penicillinase-producing staphylococci." Under our interpretation of this indication we have linked this medication with conditions we understand may be categorized as "infections caused by penicillinase-producing staphylococci." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

 ►Infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug:

  • Adults:
    • Mild to moderate infections: 125 mg every 6 hours.
    • Severe infections: 250 mg every 6 hours.
  • Children:
    • Dosages below are for patients weighing less than 40 kg. For patients 40 kg and over, use Adult dosages.
    • Mild to moderate infections: 12.5 mg/kg/day in equally divided doses every 6 hours.
    • Severe infections: 25 mg/kg/day in equally divided doses every 6 hours.
  • Dicloxacillin is best absorbed when taken on an empty stomach, and should be administered at least 1 hour before or 2 hours after meals.
  • Dicloxacillin should be taken with at least 4 fluid ounces (120 mL) of water and should not be taken in the supine position or immediately before going to bed (See PRECAUTIONS in package insert).
  • Additional information for pediatric use is in Notes below: 

How Supplied:  
  • 250 mg capsules
  • 500 mg capsules

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C).


DILAUDID (hydromorphone hydrochloride (1 mg/mL) oral solution; (2 mg; 4 mg; 8 mg) tablets)
Opioid
Prescription
Oral
Oral Solution
Tablets
Opiates/Opioids
Indications/Usage:

Indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Limitations of Use:

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [See Warnings and Precautions (5.2) in package insert], reserve DILAUDID Oral Solution and DILAUDID Tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:

  • Have not been tolerated, or are not expected to be tolerated.
  • Have not provided adequate analgesia, or are not expected to provide adequate analgesia.

Typical Dosing:  

 ►Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate:

  • Initial dosage:
    • Oral solution: Initiate treatment in a dosing range of 2.5 mL – 10 mL (2.5 mg – 10 mg) every 3 – 6 hours as needed for pain.
    • Tablets: Initiate treatment in a dosing range of 2 mg – 4 mg, orally, every 4 – 6 hours.
    • Conversion from other opioids:
      • There is inter-patient variability in the potency of opioid drugs and opioid formulations. Therefore, a conservative approach is advised when determining the total daily dosage of DILAUDID Oral Solution or DILAUDID Tablets.
      • It is safer to underestimate a patient’s 24-hour DILAUDID dosage than to overestimate the 24-hour dosage and manage an adverse reaction due to overdose.
      • In general, it is safest to start DILAUDID therapy by administering ½ of the usual starting dose every 3 – 6 hours for DILAUDID Oral Solution; and every 4 – 6 hours for DILAUDID Tablets. The dose of DILAUDID can be gradually adjusted until adequate pain relief and acceptable side effects have been achieved [See Dosage and Administration (2.4) in package insert].
    • Conversion to extended-release hydromorphone hydrochloride:
      • The relative bioavailability of DILAUDID Oral Solution and DILAUDID Tablets compared to extended-release hydromorphone hydrochloride is unknown, so conversion to extended-release tablets must be accompanied by close observation for signs of excessive sedation and respiratory depression.
  • Patients with hepatic impairment:
    • Initiate treatment with ¼ – ½ the usual DILAUDID starting dose depending on the degree of impairment [See Use in Specific Populations (8.6), and Clinical Pharmacology (12.3) in package insert].
  • Patients with renal impairment:
    • Initiate treatment with ¼ – ½ the usual DILAUDID starting dose depending on the degree of impairment [See Use in Specific Populations (8.7), and Clinical Pharmacology (12.3) in package insert].
  • Titration and maintenance of therapy:
    • Individually titrate DILAUDID Oral Solution or DILAUDID Tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving DILAUDID Oral Solution or DILAUDID Tablets to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, or misuse [See Warnings and Precautions (5.2) in package insert]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration.
    • If the level of pain increases after dosage stabilization, attempt to identify the source of increased pain before increasing the DILAUDID Oral Solution or DILAUDID Tablets dosage. If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.
    • For chronic pain, doses should be administered around-the-clock. A supplemental dose of 5% – 15% of the total daily usage may be administered every 2 hours on an as-needed basis. 
  • Discontinuation:
    • When a patient who has been taking DILAUDID Oral Solution or DILAUDID Tablets regularly and may be physically dependent no longer requires therapy with DILAUDID, taper the dose gradually, by 25% – 50% every 2 – 4 days, while monitoring carefully for signs and symptoms of withdrawal. If the patient develops these signs and symptoms, raise the dose to the previous level and taper more slowly, either by increasing the interval between decreases, decreasing the amount of change in dose, or both. Do not abruptly discontinue DILAUDID Oral Solution or DILAUDID Tablets in a physically dependent patient. [See Warnings and Precautions (5.12), Drug Abuse and Dependence (9.3) in package insert].
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • Oral solution:
    • 1 mg/mL oral solution
  • Tablets:
    • 2 mg tablets
    • 4 mg tablets
    • 8 mg tablets

Preservatives:  

Sodium metabisulfite (tablets); methylparaben, propylparaben, sodium metabisulfite (oral solution)


Storage:  
  • Store at 77°F (25°C).
  • Excursions permitted to 59° – 86°F (15° – 30°C).
  • Protect from light.


DORYX (doxycycline hyclate (50 mg; 75 mg; 100 mg; 150 mg; 200 mg) tablets, delayed-release)
Prescription
Oral
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of the following conditions or diseases: trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence; inclusion conjunctivitis caused by Chlamydia trachomatis.

Consult package insert for additional information.

This medication has a broad FDA approval for "ophthalmic infections." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "ophthalmic infections." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

 ►Trachoma or inclusion conjunctivitis:

  • The usual dosage and frequency of administration of doxycycline differs from that of other tetracyclines. Exceeding the recommended dosage may result in an increased incidence of side effects.
  • Adults:
    • The usual dose of oral doxycycline is 200 mg on the first day of treatment (administered 100 mg every 12 hours), followed by a maintenance dose of 100 mg daily.
    • The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections, 100 mg every 12 hours is recommended.
  • Children > 8 years of age:
    • The recommended dosage schedule for children weighing  45 kg is 4.4 mg/kg of body weight divided into 2 doses on the first day of treatment, followed by 2.2 mg/kg of body weight given as a single daily dose or divided into twice daily doses.
    • For children > 45 kg, the usual adult dose should be used.
  • Additional important Dosage and Administration instructions in Notes below.

How Supplied:  
  • 50 mg delayed-release tablets
  • 75 mg delayed-release tablets (generic only)
  • 100 mg delayed-release tablets (generic only)
  • 150 mg delayed-release tablets (generic only)
  • 200 mg delayed-release tablets

Preservatives:  

None listed in package insert.


Storage:  
  • Store at controlled room temperature below 77˚F (25˚C).
  • Excursions permitted to 59° – 86°F (15° – 30°C).
  • Dispense in a tight, light-resistant container.


Assistance: Payment Assistance

DORZOLAMIDE (dorzolamide hydrochloride (2%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Carbonic Anhydrase Inhibitors
Indications/Usage:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.


Typical Dosing:  

 ►Elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma:

  • Install 1 drop in the affected eye(s) 3 times daily.
  • May be used concomitantly with other topical ophthalmic drug products to lower IOP. If more than 1 topical ophthalmic drug is being used, the drugs should be administered at least 5 minutes apart.

How Supplied:  
  • 10 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59° – 86°F (15° – 30°C).
  • Protect from light.


DOXYCYCLINE MONOHYDRATE (doxycycline monohydrate capsules)
Prescription
Oral
Capsules
Tablets
Antibiotics
Indications/Usage:

Indicated for the treatment of the following infections: trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence; inclusion conjunctivitis caused by Chlamydia trachomatis.

Consult package insert for additional information.


Typical Dosing:  

Trachoma or inclusion conjunctivitis caused by Chlamydia trachomatis:

  • THE USUAL DOSAGE AND FREQUENCY OF ADMINISTRATION OF DOXYCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS.
  • Adults :
    • The usual dose is 200 mg on the first day of treatment (administered 100 mg every 12 hours or 50 mg every 6 hours), followed by a maintenance dose of 100 mg/day.
    • The maintenance dose may be administered as a single dose or as 50 mg every 12 hours. In the management of more severe infections (particularly chronic infections of the urinary tract), 100 mg every 12 hours is recommended.
  • Children:
    • For all pediatric patients weighing < 45 kg with severe or life-threatening infections (e.g. anthrax, Rocky Mountain spotted fever), the recommended dosage is 2.2 mg/kg of body weight administered every 12 hours.
    • Children weighing 45 kg should receive the adult dose (See WARNINGS and PRECAUTIONS in package insert).
    • For pediatric patients with less severe disease (> 8 years of age and weighing < 45 kg), the recommended dosage schedule is 4.4 mg per kg of body weight divided into 2 doses on the first day of treatment, followed by a maintenance dose of 2.2 mg per kg of body weight (given as a single daily dose or divided into twice daily doses).
    • For pediatric patients weighing > 45 kg, the usual adult dose should be used.
  • The therapeutic antibacterial serum activity will usually persist for 24 hours following recommended dosage.
  • Additional important Dosage and Administration instructions in Notes below.

 


How Supplied:  
  • Capsules:
    • 50 mg capsules
    • 75 mg capsules
    • 100 mg capsules
    • 150 mg capsules
  • Tablets:
    • 50 mg tablets
    • 75 mg tablets
    • 100 mg tablets
    • 150 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 68° – 77°F (20° – 25°C) (room temperature).
  • Excursions permitted to 59° – 86°F (15° – 30°C).
  • Dispense in a tight, light-resistant container.


DUREZOL (difluprednate (0.05%) ophthalmic emulsion)
Prescription
Topical
Emulsion
Anti-inflammatory Corticosteroids
Indications/Usage:

Indicated for the treatment of inflammation and pain associated with ocular surgery. Also indicated for the treatment of endogenous anterior uveitis.

This medication has FDA approval for "inflammation and pain associated with ocular surgery" and for "endogenous anterior uveitis." Under our interpretation of this indication we have linked this medication with conditions we understand to be related to "inflammation and pain associated with ocular surgery" and/or "endogenous anterior uveitis." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

 ►Inflammation and pain associated with ocular surgery: 

  • Instill 1 drop into the conjunctival sac of the affected eye(s) 4 times daily, beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period, followed by 2 times daily for a week and then a taper based on the response. 

 ►Endogenous anterior uveitis: 

  • Instill 1 drop into the conjunctival sac of the affected eye(s) 4 times daily for 14 days followed by tapering as clinically indicated.

How Supplied:  
  • 5 mL bottles

Preservatives:  

sorbic acid


Storage:  
  • Store at 59° – 77°F (15° – 25°C). 
  • Do not freeze.
  • Protect from light.
  • When not in use, keep the bottles in the protective carton.


Assistance: Payment Assistance

ELESTAT (epinastine hydrochloride (0.05%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the prevention of itching associated with allergic conjunctivitis.


Typical Dosing:  

 Itching associated with allergic conjunctivitis, recommended:

  • Instill 1 drop in each eye twice a day.
  • Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 59º – 77ºF (15º – 25ºC). 
  • Keep bottle tightly closed and out of the reach of children.


EMADINE (emedastine difumarate (0.05%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines
Indications/Usage:

Indicated for the temporary relief of the signs and symptoms of allergic conjunctivitis.


Typical Dosing:  

 Signs and symptoms of allergic conjunctivitis, recommended:

  • 1 drop  in the affected eye up to 4 times daily.

How Supplied:  
  • 5 mL bottles

Preservatives:  

benzalkonium chloride


Storage:  
  • Store at 39° – 86°F (4° – 30°C).


EPINASTINE (epinastine hydrochloride (0.05%) ophthalmic solution)
Prescription
Topical
Ophthalmic Solution
Antihistamines and Mast Cell Stabilizer Combinations
Indications/Usage:

Indicated for the prevention of itching associated with allergic conjunctivitis.


Typical Dosing:  

 Itching associated with allergic conjunctivitis, recommended:

  • Instill 1 drop in each eye twice a day.
  • Treatment should be continued throughout the period of exposure (i.e., until the pollen season is over or until exposure to the offending allergen is terminated), even when symptoms are absent.

How Supplied:  
  • 5 mL bottles

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 59º – 77ºF (15º – 25ºC). 
  • Keep bottle tightly closed and out of the reach of children.


ERYTHROMYCIN (erythromycin (0.5%) ophthalmic ointment)
Prescription
Topical
Ointment
Antibiotics
Indications/Usage:

Indicated for the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin and for prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established.

This medication has a broad FDA approval for "superficial ocular infections involving the conjunctiva and/or cornea." Under our interpretation of this indication we have linked this medication with conditions we understand to be categorized as "superficial ocular infections involving the conjunctiva and/or cornea." This is our medical opinion and may not be true in all clinical circumstances.

Typical Dosing:  

►Superficial ocular infections:

  • Approximately 1 cm in length should be applied directly to the infected eye(s) up to 6 times daily, depending on the severity of the infection.

Neonatal gonococcal or chlamydial ophthalmia, prophylaxis:

  • A ribbon of ointment approximately 1 cm in length should be instilled into each lower conjunctival sac. The ointment should not be flushed from the eye following instillation. A new tube should be used for each infant.

How Supplied:  
  • 1 g tubes
  • 3.5 g tubes

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store between 59° – 77°F (15° – 25°C).


EYLEA (aflibercept (2 mg/0.05 mL) intravitreal injection )
Prescription
Injectable
Intravitreal
VEGF Inhibitors
Indications/Usage:

Indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.


Typical Dosing:  

 Neovascular (wet) age-related macular degeneration, recommended:  

  • 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).
  • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated when EYLEA was dosed every 4 weeks compared to every 8 weeks. [See Clinical Studies (14.1) in package insert].
  • Some patients may need every 4 week (monthly) dosing after the first 12 weeks (3 months).
  • Although not as effective as the recommended every 8 week dosing regimen, patients may also be treated with one dose every 12 weeks after one year of effective therapy.
  • Patients should be assessed regularly.
  • Additional information for Dosage and Administration is in Notes below.

►Macular edema following retinal vein occlusion, recommended:

  • 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (approximately every 25 days, monthly). [See Clinical Studies (14.2), (14.3) in package insert].
  • Additional information for Dosage and Administration is in Notes below.

►Diabetic macular edema, recommended:

  • 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).
  • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks [See Clinical Studies (14.4) in package insert].
  • Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).
  • Additional information for Dosage and Administration is in Notes below.

Diabetic retinopathy, recommended:

  • The recommended dose for EYLEA is 2 mg (0.05 mL or 50 microliters) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 5 injections, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks (2 months).
  • Although EYLEA may be dosed as frequently as 2 mg every 4 weeks (approximately every 25 days, monthly), additional efficacy was not demonstrated in most patients when EYLEA was dosed every 4 weeks compared to every 8 weeks [see Clinical Studies (14.5) in package insert].
  • Some patients may need every 4 week (monthly) dosing after the first 20 weeks (5 months).
  • Additional information for Dosage and Administration is in Notes below.

How Supplied:  
  • Single-use vial in carton, including:
    • (1) EYLEA 2 mg/0.05 mL single dose glass vial
    • (1) 19 gauge × 1 1⁄2 inch, 5 micron, filter needle for withdrawal of the vial contents
    • (1) 30 gauge × 1⁄2 inch injection needle for intravitreal injection
    • (1) 1 mL syringe for administration
    • package insert
  • Consult package insert for additional information.

Preservatives:  

None listed in package insert.


Storage:  
  • Store under refrigeration at 36° – 46°F (2° – 8°C). 
  • Do not freeze. 
  • Do not use beyond the date stamped on the carton and container label.
  • Protect from light.
  • Store in the original carton until time of use.


Assistance: Payment Assistance

FAMCICLOVIR (famciclovir (125 mg; 250 mg; 500 mg) tablets)
Prescription
Oral
Tablets
Antivirals
Indications/Usage:

Indicated for the treatment of acute herpes zoster (shingles).

The efficacy of famciclovir when initiated more than 72 hours after onset of rash has not been established.

Limitations of use:

  • The efficacy and safety of famciclovir have not been established for:
  • Patients < 18 years of age.
  • Patients with ophthalmic zoster
  • Immunocompromised patients other than for the treatment of recurrent orolabial or genital herpes in HIV-infected patients.
  • Black and African American patients with recurrent genital herpes.

Typical Dosing:  

►Acute herpes zoster (shingles):

  • 500 mg every 8 hours for 7 days.
  • Therapy should be initiated as soon as herpes zoster is diagnosed.

►Acute herpes simplex keratitis:

  • 250 mg every 8 hours for 7 – 10 days.
Dosing for herpes simplex keratitis is based on professional judgment. This is our medical opinion and may not be true in all clinical circumstances.​​​​​​​​​​​​​​

How Supplied:  
  • 125 mg tablets
  • 250 mg tablets
  • 500 mg tablets

Preservatives:  

Preservatives may vary across product manufacturers. Consult individual package inserts.


Storage:  
  • Store at 77°F (25°C).
  • Excursions permitted to 59° – 86°F (15° – 30°C).


223 items found